Market capitalisation of Suven Pharma, as on Friday, was ₹12,682.43 crore. ET was the first to report on the sale on December 23. Advent is using Cohance Lifesciences as the vehicle for the acquisition. The platform was created last month for its active pharmaceutical ingredient (API) and contract development and manufacturing businesses comprising three portfolio companies – RA Chem Pharma, ZCL Chemicals and Avra Laboratories.